Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00280
|
|||||
| Drug Name |
Nicardipine
|
|||||
| Synonyms |
2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Cardene (TN); Cardene IV; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Nicardipine (INN); Nicardipine LA; Nicardipine [INN:BAN]; Nicardipino; Nicardipino [INN-Spanish]; Nicardipinum; Nicardipinum [INN-Latin]; Y-93
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Angina [ICD11:BA40] | Approved | [1] | |||
| High blood pressure [ICD11:BA00] | Approved | [1] | ||||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H29N3O6
|
|||||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
|
|||||
| InChI |
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
|
|||||
| InChIKey |
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 55985-32-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 479.5 | Topological Polar Surface Area | 114 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11119969
,11120457
,11120945
,11121454
,11121934
,11147052
,11335715
,11360954
,11362523
,11364266
,11365085
,11366828
,11367647
,11369390
,11370317
,11370318
,11372542
,11373248
,11373883
,11375809
,11377552
,11461926
,11466411
,11467531
,11485226
,11486222
,11489231
,11491267
,11492237
,11495186
,14907905
,26755701
,26755702
,29223569
,46504482
,47216524
,47216525
,47515065
,47588738
,47810485
,47810486
,47810487
,47810488
,48034827
,48184723
,6300545
,7578094
,7980119
,8152757
,9473
|
|||||
| ChEBI ID |
ChEBI:7550
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km =2.6 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [3] | |
| References | ||||||
| 1 | Nicardipine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.